Capricor Therapeutics, Inc.
CAPR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -30.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -65.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -63.9% |
| EPS Diluted | -0.54 | -0.57 | -0.53 | -0.16 |
| % Growth | 5.3% | -7.5% | -231.3% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |